MedPath

Improving HIV Prevention Among Adolescent Girls and Young Women (AGYW) in Uganda

Not Applicable
Completed
Conditions
HIV-1-infection
Interventions
Other: Peer Support
Registration Number
NCT05516602
Lead Sponsor
MRC/UVRI and LSHTM Uganda Research Unit
Brief Summary

Purpose: The purpose of the project is to evaluate a peer support intervention aimed at improving uptake of and adherence to oral PrEP.

Main Study Aim:

To evaluate a peer support intervention aimed at improving uptake of and adherence to oral pre-exposure prophylaxis (PrEP), and its effect on sexual behavioral and reproductive health outcomes

Study Objectives:

i. To evaluate the effect of a peer support intervention on uptake of and adherence to oral PrEP among 14-24-year-old AGYW at risk of HIV infection in Kampala, Uganda.

ii. To evaluate the effect of the peer support intervention aimed at improving oral PrEP uptake and adherence, on sexual behavior and reproductive health outcomes among AGYW in Kampala, Uganda.

Design An individually randomized controlled trial with parallel group design and 1:1 randomization in the intervention and control arms.

Population: 14-24-year old AGYW at risk of HIV infection in Kampala.

Control arm: Standard health worker counselling during clinic visits.

Intervention arm: Standard health worker counselling during clinic visits + peer support groups over the weekend.

Detailed Description

1 INTRODUCTION 1.1 Background Adolescent girls and young women (AGYW) aged 15-24 years in Sub-Saharan Africa (SSA) are at substantial risk for HIV infection and in 2020, AGYW accounted for 32% of new HIV infections in East and Southern Africa \[1\]. In the general population in Uganda, the HIV prevalence among AGYW is estimated at 1.8% among 15-19 year-olds and 5.1% among 20-24 year-olds \[2\]. The prevalence among AGYW living in fishing communities in Uganda, and young female sex workers (FSWs) is even higher estimated at 15.4% and 22.5% respectively \[3, 4\]. During recent years, biomedical interventions for HIV prevention have been developed and are currently at different stages of the pipeline with some already approved for use. For example, anti-retroviral (ARV) implants for pre-exposure prophylaxis (PrEP) to protect HIV negative girls from becoming HIV infected, have recently been assessed in pre-clinical studies \[5, 6\]. Other biomedical interventions for HIV prevention among vulnerable HIV negative sub-groups, including AGYW in SSA, have further been assessed in clinical trials for example: the Dapivirine vaginal ring (DVR) \[7, 8\], long acting injectable PrEP \[9, 10\], HIV vaccines \[11\] and oral PrEP \[12, 13\]. Oral PrEP is a single pill taken once daily during periods of risk to HIV infection, and is highly efficacious when adherence is good (\>90%) \[12\]. Tenofovir is one of the most common HIV drugs and tenofovir-based oral PrEP is also one of the World Health Organization (WHO) approved biomedical HIV prevention interventions \[14, 15\]. In 2016, the Uganda government approved use of oral PrEP for HIV prevention among individuals at substantial risk of HIV infection \[16\], and increased access to targeted key populations including AGYW. The HIV prevention landscape is promising as other novel biomedical HIV prevention interventions are in various stages of development, including long acting injectable PrEP, anti-retroviral (ARV) implants and HIV vaccines. The Dapivirine vaginal ring is approved by WHO as an additional HIV prevention choice for women \[17\], has been approved for use in South Africa \[18\] and, has been added to the drug register of the National Drug Authority in Uganda \[19\]. Injectable cabotegravir may also be available soon having shown efficacy in the HIV Prevention Trials Network (HPTN084) study \[10\]. End-user preferences for HIV prevention products may predict method uptake \[20\] and there is a need to increase researchers' knowledge about current preferences for HIV prophylaxis among AGYW in SSA who continue to be at substantial risk of HIV.

1.2 Oral PrEP Uptake and Adherence among Adolescent Girls and Young Women Oral PrEP is still currently the only available biomedical HIV prevention method in most parts of SSA. PrEP implementation projects have been facilitated through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) funding. Despite the potential benefits in HIV prevention, uptake and adherence to oral PrEP remain low among AGYW in Uganda and other parts of SSA \[21, 22\]. A recent study among AGYW in Kampala, Uganda, with high reported prevalence of being engaged in sex for compensation, also found a low oral PrEP uptake (31%) in this population \[23\]. The study also found that the uptake was higher in respondents with more sexual partners and among those who showed higher preference for oral PrEP over other biomedical HIV prevention methods when asked at enrolment. Importantly, tests for Tenofovir levels in blood showed very low adherence. Conversely, the Prevention Options for Women Evaluation Research (POWER) project which also enrolled 16-25-year-old AGYW in Kenya and South Africa reported high PrEP uptake (90%) associated with higher risk behavior, intimate partner violence (IPV), depression and chlamydia/ gonorrhea diagnosis \[24\]. Despite high PrEP uptake, the POWER project reported early discontinuation of PrEP use due to side effects, challenges with accessing services and product characteristics such as need for daily dosing \[24, 25\]. Other studies have identified pill burden, side effects \[21, 22\], low risk perception \[26, 27\] and limited awareness of oral PrEP \[28\] as barriers to PrEP uptake among AGYW in SSA. Interviews with potential PrEP users in multiple settings in central Uganda also showed that stigma, transport costs to get PrEP refills, accessibility, busy schedules, and forgetfulness were barriers to PrEP uptake while closeness of PrEP providers to one's home was a facilitator \[29\]. Thus, there is a need for interventions that may promote PrEP use among AGYW populations in SSA who are at increased risk of HIV infection.

1.3 Rationale Peer-to-peer support is one of the strategies proposed for improving HIV prevention and promotion of safer sexual behaviors in the Uganda National HIV research agenda \[30\], but there is limited evidence of its effectiveness in PrEP programs. Studies show that young people easily take on behaviors when in groups than as individuals, easily adopt behaviors and norms of their peers \[31, 32\], and are more easily affected by peer influence compared to children and older adults \[33\]. Among young people living with HIV in Zimbabwe, peer-led psycho-social support services among HIV positive individuals led to a 13% decrease in detectable viremia at 6 months compared with counselling delivered by health care workers (HCWs) \[34\]. A recent study among refugee adolescents in Northern Uganda showed same day acceptance of contraception was 9% higher among those who received peer counselling compared to counselling provided by HCWs \[35\]. In addition, trained peers have led to improvements in the HIV care and treatment cascade and contraceptive use through peer counselling, peer support for example delivery of interventions, peer referral etc. \[36, 37\]. Previous evidence suggests that peer counselling and support interventions have improved HIV testing, utilization of health care services, anti-retroviral therapy (ART) initiation, adherence to treatment, adherence to HIV viral load testing at 6 months and HIV viral suppression among young people living with HIV in Zimbabwe \[37, 38\]. Peer support interventions may therefore also improve oral PrEP uptake and adherence, and also reduce sexual behavior risk among AGYW, but this has not been widely studied.

2. STUDY AIMS AND RESEARCH QUESTIONS 2.1 The main aim of this project is to evaluate the effect of a peer support intervention on oral PrEP uptake and adherence, sexual behavioral and reproductive health outcomes of 14-24-year-old AGYW who are at high risk of HIV infection.

2.2 Research Questions i. What is the effect of a peer support intervention on uptake of and adherence to oral PrEP among AGYW aged 14-24 years at high risk of HIV infection in Uganda? ii. What are the effects of a peer support intervention for oral PrEP uptake and adherence on sexual behavior and reproductive health outcomes of AGYW aged 14-24 years at high risk of HIV infection in Uganda?

The investigators hypothesize that the peer support intervention will: (i) improve oral PrEP uptake and adherence among AGYW; (ii) reduce sexual behavioral risk, pregnancy and sexually transmitted infection (STI) rates

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
394
Inclusion Criteria
  • HIV negative (assessed through rapid blood test)
  • Sexually active in the past 3 months
  • 14-24 years
  • Hepatitis B negative for those who initiate oral PrEP
  • Willing to undergo study procedures
Exclusion Criteria
  • HIV infection
  • Currently taking oral PrEP
  • Known allergy to common medications, components of oral PrEP or contraceptives
  • Pregnant
  • An acute or chronic illness that may affect volunteer participation or achieving study objectives
  • A condition or situation that in the opinion of the PI/designee would preclude provision of informed consent, or otherwise interfere with achieving the study objectives

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Peer SupportPeer SupportStandard health worker counselling during clinic visits plus peer support over the weekends.
Primary Outcome Measures
NameTimeMethod
The proportion of enrolled participants who take up oral PrEP after randomization to peer support or the standardMeasured from enrolment to the end of follow up at 12 months

Number of participants who take up oral PrEP divided by the total number enrolled. PrEP uptake was measured as a participants accepting the offer of oral PrEP and picking their first month's supply from the clinic.

The proportion of volunteers who take up oral PrEP and adhere to oral PrEP after randomization to peer support or the standard3 monthly measurements from enrolment to the end of follow up at 12 months

Number of participants who adhere to oral PrEP divided by the total number taking oral PrEP. Adherence was measured using self reports, pill counts and rapid urine tenofovir kits

Time in days to oral PrEP uptake from the date it is offered after randomization to peer support or the standard.Measured from enrolment to the end of follow up at 12 months

Number of days from the date a participant is offered oral PrEP to the date they pick the first month's supply from the clinic.

Secondary Outcome Measures
NameTimeMethod
Total number of sexual partners in the past 3 months in the peer support group compared to the standard3 monthly measurements from enrolment to the end of follow up at 12 months

Proportion of participants having a specific risk score for total sexual partners in the past 3 months comparing the peer support group and the standard. Risk scores 1-4 assigned for number of sexual partners in the past 3 months as follows:

* 0= no sexual partners

* 1= 1 sexual partner

* 2= 2-4 sexual partners

* 3= 5-9 sexual partners

* 4= ≥10 sexual partners

STI and pregnancy incidence at follow up in the peer support group compared to the standard3 monthly measurements from enrolment to the end of follow up at 12 months

The number of new STI infections and pregnancies recorded every 3 months in the peer support group compared to the standard.

Having an incident STI (Yes/ No) defined as the first new diagnosis of chlamydia and/ or gonorrhoea (positive urine GeneXpert) in a participant who tested negative for either STI (negative urine GeneXpert) at enrolment.

Having an incident pregnancy (Yes/ No) defined as the first new pregnancy (positive urine βHCG) in a participant who was not pregnant (negative urine βHCG ) at enrolment.

Condom use with total sexual partners in the past 3 months in the peer support groups compared to the control3 monthly measurements from enrolment to study end at 12 months

Proportion of participants with a specific risk score for reported condom use with total sexual partners in the past 3 months comparing the peer support groups and the control. Risk scores assigned for reported condom use with sexual partners in the past 3 months as follows:

* 1= used condoms always

* 2= used condoms most times

* 3= used condoms sometimes

* 4= did not use condoms at all

The proportion of participants who are not using a modern contraceptive at baseline and take up a modern contraceptive method at any time during the study3 monthly measurements from enrolment to the end of follow up at 12 months

Number of participants who take up a modern contraceptive method during the study.

Contraceptive uptake (Yes/ No) defined as a participant who reported not using contraception at enrolment taking up a contraceptive method at any time during the study.

Trial Locations

Locations (1)

MRC/UVRI and LSHTM

🇺🇬

Entebbe, Uganda

© Copyright 2025. All Rights Reserved by MedPath